Merck (MRK) Assets Average (2009 - 2026)
Merck (MRK) posted quarterly Assets Average of $132.8 billion for Q1 2026, up 14.35% year-over-year from $116.1 billion in Q1 2025, and little changed quarter-over-quarter from $133.2 billion in Q4 2025.
Merck (MRK) Assets Average (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Assets Average for 18 consecutive years, with $132.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 14.35% year-over-year to $132.8 billion; the TTM figure through Mar 2026 stood at $132.8 billion (up 14.35% YoY), while the FY2025 annual figure was $127.0 billion, up 13.49% from the prior year.
- Assets Average steadied at $132.8 billion in Q1 2026 per MRK's latest filing, from $133.2 billion in the prior quarter.
- Across five years, Assets Average topped out at $133.2 billion in Q4 2025 and bottomed at $105.6 billion in Q3 2023.
- Historically, Assets Average has averaged $113.2 billion across 5 years, with a median of $108.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Assets Average gained 17.75% — and 2024, when it decreased 2.04%.
- Merck's Assets Average stood at $108.1 billion in 2022, then dropped by 1.31% to $106.7 billion in 2023, then advanced by 9.95% to $117.3 billion in 2024, then grew by 13.54% to $133.2 billion in 2025, then fell by 0.32% to $132.8 billion in 2026.
- Business Quant data shows MRK's Assets Average at $132.8 billion in Q1 2026, $133.2 billion in Q4 2025, and $123.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.24 Bn |
| Mar 31, 2026 | 132.78 Bn |
| Dec 31, 2025 | 133.21 Bn |
| Sep 30, 2025 | 123.53 Bn |
| Jun 30, 2025 | 116.32 Bn |
| Mar 31, 2025 | 116.11 Bn |
| Dec 31, 2024 | 117.32 Bn |
| Sep 30, 2024 | 115.08 Bn |
| Jun 30, 2024 | 109.24 Bn |
| Mar 31, 2024 | 106.26 Bn |
| Dec 31, 2023 | 106.70 Bn |
| Sep 30, 2023 | 105.60 Bn |
| Jun 30, 2023 | 106.13 Bn |
| Mar 31, 2023 | 108.48 Bn |
| Dec 31, 2022 | 108.12 Bn |
| Sep 30, 2022 | 107.09 Bn |
| Jun 30, 2022 | 106.88 Bn |
| Mar 31, 2022 | 106.18 Bn |
| Dec 31, 2021 | 99.59 Bn |
| Sep 30, 2021 | 92.09 Bn |